HAE

Haemonetics Corporation (HAE) | Rumor.io

Haemonetics

HAE

Attention (50-day avg)0%

Attention rank (50-day avg)#3,125

Bullish sentiment (50-day avg)100%

Price to earnings ratio50.9

Market capitalization4.8B

Earnings per share2.07

Dividend yield (TTM)—

Revenue (annual)1.3B

Net income (annual)97.3M

Social

What share of all stock conversation is about HAE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 18

Haemonetics Corporation ($HAE) has signed a supply agreement with CSL Plasma Inc., with CSL expected to transition a portion of its US plasma collection centers to Haemonetics' devices and disposables.
The supply agreement is non-exclusive and does not contain minimum purchase commitments, with Haemonetics anticipating CSL to transition a portion of its US plasma collection centers to its devices and disposables.
Haemonetics' stock price has risen significantly following the announcement, with some analysts raising their price objectives for the company.

Generated by AI

Sentiment

Of the messages about HAE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% 0	35% -19.64
Bearish	0%	0% 0	0% 0	65% +19.64

Bullish· May 13

Analyst Mike Matson maintains a buy rating for $HAE with a price target of $86.00.
The stock has strong support near $40 and potential for upside to $100+ over the next year.
Analyst consensus is 80% buy, indicating mild confidence in $HAE's future performance.

Bearish· May 13

Haemonetics Corporation's Q4 earnings missed estimates, and the company provided downside Q1 guidance.
The company's blood plasma business suffered from the pandemic, leading to a 12% year-over-year revenue decline in fiscal 2021.
Haemonetics' earnings per share (EPS) missed estimates by $0.21, despite beating on revenue.

Generated by AI

Topics

Of the messages about HAE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	100%	100%	50%	24.93%
Announcements	0%	0%	50%	33.7%
Technical Analysis	0%	0%	0%	34.52%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.82%
Macro	0%	0%	0%	6.03%

Earnings· Nov 7

Haemonetics Corporation ($HAE) reported FQ2 earnings of $0.48 EPS, beating consensus estimates by $0.07.
Revenue for the quarter was $225.38M, also beating expectations.
The company raised its FY18 EPS guidance above consensus and reaffirmed its FY18 revenue guidance.

Analysts· May 14

Haemonetics Corporation ($HAE) has received upgrades and positive ratings from several analysts, including CJS Securities, JMP Securities, and Jefferies Financial Group Inc.
Analysts have lowered price targets for $HAE, with Barrington Research cutting its target to $71.00, JMP Securities to $90.00, and Morgan Stanley to $75.00.
The consensus among analysts is mildly positive, with 80% of analysts recommending a "buy" rating, according to a recent analysis.

Generated by AI

Community

Of the messages about HAE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	17.65%	19.77%
Newcomers	100%	100%	82.35%	80.23%

Regulars· May 11

Haemonetics reported Q4 EPS of $0.77, beating the estimated $0.68, and sales of $304M, exceeding the predicted $290.79M.
The company's Q4 earnings release is available on its investor relations website, and the SEC filing has been made public.
Haemonetics guided FY24 EPS above consensus expectations, while revenue is expected to be in line with estimates.

Newcomers· Nov 7

Haemonetics Corporation (HAE) stock has seen a significant surge of 22% after strong earnings and guidance beat, making it a potential blood-booster for investors.
The company's stock price rose after Bank of America upgraded its rating to "neutral" due to prudent growth forecasts, indicating a positive outlook for Haemonetics.
Haemonetics' stock price has reclaimed key technical levels near $65, with next resistance sitting around $72-$75, and the company's stock has erased months of losses following the earnings-driven breakout.

Generated by AI

Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...

7d agoYahoo Finance

Haemonetics Shares Rise After Citigroup Upgrade

Haemonetics (HAE) shares were up over 2% in Thursday trading after Citigroup upgraded the stock to b

12d agoYahoo Finance

Haemonetics stock hits 52-week high at 109.6 USD

12d agoInvesting.com

Haemonetics stock upgraded at Bank of America (HAE:NYSE)

12d agoSeeking Alpha

Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92

Haemonetics (HAE) has an average rating of overweight and mean price target of $108.40, according to

13d agofinance.yahoo.com

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

Orchestra BioMed (OBIO) said Tuesday it has received $6.1 million as a milestone payment in connecti

15d agoYahoo Finance

Also Discussed

Investors talking about HAE also mention

#	Name	Attention
1	Grifols S.A. ADRGRFS	0%0
2	ABMD - Abiomed, Inc.	——
3	Edwards Lifesciences CorporationEW	0%new
4	AMWD - American Woodmark Corporation	——
5	LivaNova PLCLIVN	0%0
6	Hawaiian Electric Industries, Inc.HE	0.01%+0.01
7	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0
8	AXNX - Axonics, Inc.	——
9	PRA Group Inc.PRAA	0%0
10	STERIS plcSTE	0%0

Haemonetics Corporation

Healthcare
Medical Devices

Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency. The Blood Center segment offers apheresis and whole blood collection solutions used to collect and process blood components for transfusion. The Hospital segment includes blood management technologies, hemostasis management systems, surgical blood salvage products, vascular closure devices, and sensor-guided tools designed to support clinical decision-making and procedural performance. Headquartered in Boston, Massachusetts, Haemonetics serves healthcare providers and collection centers across global markets.

Website

Location

125 Summer Street

Boston, MA, 02110

United States

Social

What share of all stock conversation is about HAE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 18

Haemonetics Corporation ($HAE) has signed a supply agreement with CSL Plasma Inc., with CSL expected to transition a portion of its US plasma collection centers to Haemonetics' devices and disposables.
The supply agreement is non-exclusive and does not contain minimum purchase commitments, with Haemonetics anticipating CSL to transition a portion of its US plasma collection centers to its devices and disposables.
Haemonetics' stock price has risen significantly following the announcement, with some analysts raising their price objectives for the company.

Generated by AI

Sentiment

Of the messages about HAE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% 0	35% -19.64
Bearish	0%	0% 0	0% 0	65% +19.64

Bullish· May 13

Analyst Mike Matson maintains a buy rating for $HAE with a price target of $86.00.
The stock has strong support near $40 and potential for upside to $100+ over the next year.
Analyst consensus is 80% buy, indicating mild confidence in $HAE's future performance.

Bearish· May 13

Haemonetics Corporation's Q4 earnings missed estimates, and the company provided downside Q1 guidance.
The company's blood plasma business suffered from the pandemic, leading to a 12% year-over-year revenue decline in fiscal 2021.
Haemonetics' earnings per share (EPS) missed estimates by $0.21, despite beating on revenue.

Generated by AI

Topics

Of the messages about HAE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	100%	100%	50%	24.93%
Announcements	0%	0%	50%	33.7%
Technical Analysis	0%	0%	0%	34.52%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.82%
Macro	0%	0%	0%	6.03%

Earnings· Nov 7

Haemonetics Corporation ($HAE) reported FQ2 earnings of $0.48 EPS, beating consensus estimates by $0.07.
Revenue for the quarter was $225.38M, also beating expectations.
The company raised its FY18 EPS guidance above consensus and reaffirmed its FY18 revenue guidance.

Analysts· May 14

Haemonetics Corporation ($HAE) has received upgrades and positive ratings from several analysts, including CJS Securities, JMP Securities, and Jefferies Financial Group Inc.
Analysts have lowered price targets for $HAE, with Barrington Research cutting its target to $71.00, JMP Securities to $90.00, and Morgan Stanley to $75.00.
The consensus among analysts is mildly positive, with 80% of analysts recommending a "buy" rating, according to a recent analysis.

Generated by AI

Community

Of the messages about HAE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	17.65%	19.77%
Newcomers	100%	100%	82.35%	80.23%

Regulars· May 11

Haemonetics reported Q4 EPS of $0.77, beating the estimated $0.68, and sales of $304M, exceeding the predicted $290.79M.
The company's Q4 earnings release is available on its investor relations website, and the SEC filing has been made public.
Haemonetics guided FY24 EPS above consensus expectations, while revenue is expected to be in line with estimates.

Newcomers· Nov 7

Haemonetics Corporation (HAE) stock has seen a significant surge of 22% after strong earnings and guidance beat, making it a potential blood-booster for investors.
The company's stock price rose after Bank of America upgraded its rating to "neutral" due to prudent growth forecasts, indicating a positive outlook for Haemonetics.
Haemonetics' stock price has reclaimed key technical levels near $65, with next resistance sitting around $72-$75, and the company's stock has erased months of losses following the earnings-driven breakout.

Generated by AI

Haemonetics

Social

Aug 18

Bullish· May 13

Bearish· May 13

Earnings· Nov 7

Analysts· May 14

Regulars· May 11

Newcomers· Nov 7

Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus

Haemonetics Shares Rise After Citigroup Upgrade

Haemonetics stock hits 52-week high at 109.6 USD

Haemonetics stock upgraded at Bank of America (HAE:NYSE)

Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

Also Discussed

Haemonetics Corporation

Company Information

Location

Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus

Haemonetics Shares Rise After Citigroup Upgrade

Haemonetics stock hits 52-week high at 109.6 USD

Haemonetics stock upgraded at Bank of America (HAE:NYSE)

Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

Also Discussed

Social

Aug 18

Bullish· May 13

Bearish· May 13

Earnings· Nov 7

Analysts· May 14

Regulars· May 11

Newcomers· Nov 7